Journal article

Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder

David R Coghill, Jeffrey H Newcorn, Jie Chen, Tamara Werner-Kiechle, Tobias Banaschewski

Journal of Psychopharmacology | SAGE PUBLICATIONS LTD | Published : 2020


INTRODUCTION AND OBJECTIVES: Lack of consensus regarding how best to define treatment response hinders translation from trials to the clinic. These post hoc analyses examine three commonly used response criteria in six trials of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHODS: Data from four short-term randomised controlled trials (RCTs) and two long-term open-label studies were analysed. Children and adolescents with ADHD received either dose-optimised (30-70 mg/day) or fixed-dose (70 mg/day) LDX. The RCTs included osmotic-release oral system methylphenidate (OROS-MPH) or atomoxetine (ATX) as a head-to-head comparat..

View full abstract


Funding Acknowledgements

We thank the participants and investigators involved in the studies. This post hoc analysis and the six original studies were funded by the sponsor, Shire Development LLC, a member of the Takeda group of companies. Under the direction of the authors and funded by Shire International GmbH, a member of the Takeda group of companies, Dr TJ van Hartevelt and Dr E Southam of Oxford PharmaGenesis provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing and fact checking was also provided by Oxford PharmaGenesis. Although employees of the sponsor were involved in the study design, data collection, analysis and interpretation, and fact checking of information, the content of this manuscript, the interpretation of the data and the decision to submit the manuscript for publication in Journal of Psychopharmacology was made by the authors independently.